Overview

A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia

Status:
Withdrawn
Trial end date:
2021-01-24
Target enrollment:
Participant gender:
Summary
This is a single-arm, multi-center, open-label, Phase 2 study to determine the efficacy and safety of JCAR015 in adult subjects with B-cell ALL. The study is divided into two sequential parts, Part A and Part B; subjects will be screened and will provide informed consent before initiating any study procedures in Part A of the study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Celgene
Celgene Corporation
Collaborator:
Juno